Response to long-term growth hormone therapy in short children with reduced GH bioactivity

Paola Travaglino, Fabio Buzi, Cristina Meazza, Sara Pagani, Carmine Tinelli, Lorenzo Iughetti, Vincenzo De Sanctis, Gianluca Aimaretti, Dimitri Poddighe, Salvatore Barberi, Mauro Bozzola

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bioinactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods: We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels (>10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak <5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peak time for each patient during the provocative test was significantly lower in bioinactive GH than in GHD children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalHormone Research
Volume66
Issue number4
DOIs
Publication statusPublished - Sep 1 2006
Externally publishedYes

Fingerprint

Growth Hormone
Therapeutics
Growth
Serum
Human Growth Hormone

Keywords

  • Growth hormone bioinactivity
  • Growth hormone deficiency
  • Growth hormone treatment
  • Growth velocity
  • Nb cell bioassay

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Travaglino, P., Buzi, F., Meazza, C., Pagani, S., Tinelli, C., Iughetti, L., ... Bozzola, M. (2006). Response to long-term growth hormone therapy in short children with reduced GH bioactivity. Hormone Research, 66(4), 189-194. https://doi.org/10.1159/000094483

Response to long-term growth hormone therapy in short children with reduced GH bioactivity. / Travaglino, Paola; Buzi, Fabio; Meazza, Cristina; Pagani, Sara; Tinelli, Carmine; Iughetti, Lorenzo; De Sanctis, Vincenzo; Aimaretti, Gianluca; Poddighe, Dimitri; Barberi, Salvatore; Bozzola, Mauro.

In: Hormone Research, Vol. 66, No. 4, 01.09.2006, p. 189-194.

Research output: Contribution to journalArticle

Travaglino, P, Buzi, F, Meazza, C, Pagani, S, Tinelli, C, Iughetti, L, De Sanctis, V, Aimaretti, G, Poddighe, D, Barberi, S & Bozzola, M 2006, 'Response to long-term growth hormone therapy in short children with reduced GH bioactivity', Hormone Research, vol. 66, no. 4, pp. 189-194. https://doi.org/10.1159/000094483
Travaglino P, Buzi F, Meazza C, Pagani S, Tinelli C, Iughetti L et al. Response to long-term growth hormone therapy in short children with reduced GH bioactivity. Hormone Research. 2006 Sep 1;66(4):189-194. https://doi.org/10.1159/000094483
Travaglino, Paola ; Buzi, Fabio ; Meazza, Cristina ; Pagani, Sara ; Tinelli, Carmine ; Iughetti, Lorenzo ; De Sanctis, Vincenzo ; Aimaretti, Gianluca ; Poddighe, Dimitri ; Barberi, Salvatore ; Bozzola, Mauro. / Response to long-term growth hormone therapy in short children with reduced GH bioactivity. In: Hormone Research. 2006 ; Vol. 66, No. 4. pp. 189-194.
@article{e0e44d990b0f47c0be55de0bc44dbbcd,
title = "Response to long-term growth hormone therapy in short children with reduced GH bioactivity",
abstract = "Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bioinactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods: We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels (>10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak <5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peak time for each patient during the provocative test was significantly lower in bioinactive GH than in GHD children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height.",
keywords = "Growth hormone bioinactivity, Growth hormone deficiency, Growth hormone treatment, Growth velocity, Nb cell bioassay",
author = "Paola Travaglino and Fabio Buzi and Cristina Meazza and Sara Pagani and Carmine Tinelli and Lorenzo Iughetti and {De Sanctis}, Vincenzo and Gianluca Aimaretti and Dimitri Poddighe and Salvatore Barberi and Mauro Bozzola",
year = "2006",
month = "9",
day = "1",
doi = "10.1159/000094483",
language = "English",
volume = "66",
pages = "189--194",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Response to long-term growth hormone therapy in short children with reduced GH bioactivity

AU - Travaglino, Paola

AU - Buzi, Fabio

AU - Meazza, Cristina

AU - Pagani, Sara

AU - Tinelli, Carmine

AU - Iughetti, Lorenzo

AU - De Sanctis, Vincenzo

AU - Aimaretti, Gianluca

AU - Poddighe, Dimitri

AU - Barberi, Salvatore

AU - Bozzola, Mauro

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bioinactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods: We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels (>10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak <5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peak time for each patient during the provocative test was significantly lower in bioinactive GH than in GHD children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height.

AB - Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bioinactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods: We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels (>10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak <5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peak time for each patient during the provocative test was significantly lower in bioinactive GH than in GHD children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height.

KW - Growth hormone bioinactivity

KW - Growth hormone deficiency

KW - Growth hormone treatment

KW - Growth velocity

KW - Nb cell bioassay

UR - http://www.scopus.com/inward/record.url?scp=33748796632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748796632&partnerID=8YFLogxK

U2 - 10.1159/000094483

DO - 10.1159/000094483

M3 - Article

VL - 66

SP - 189

EP - 194

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 4

ER -